The portfolio maintains a sizable cost advantage over competitors, priced within the lowest fee quintile among peers.
Roundhill GLP-1 & Weight Loss ETF OZEM
Morningstar’s Analysis OZEM
Will OZEM outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 65.4
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Novo Nordisk AS ADR | 17.16 | 7.9 Mil | Healthcare |
Eli Lilly and Co | 16.16 | 7.5 Mil | Healthcare |
Roche Holding AG | 4.74 | 2.2 Mil | Healthcare |
Zealand Pharma AS | 4.53 | 2.1 Mil | Healthcare |
Chugai Pharmaceutical Co Ltd | 4.32 | 2.0 Mil | Healthcare |
AstraZeneca PLC ADR | 4.09 | 1.9 Mil | Healthcare |
Viking Therapeutics Inc | 3.87 | 1.8 Mil | Healthcare |
Innovent Biologics Inc | 3.68 | 1.7 Mil | Healthcare |
Structure Therapeutics Inc ADR | 3.64 | 1.7 Mil | Healthcare |
Altimmune Inc | 3.21 | 1.5 Mil | Healthcare |